TomoTherapy (TOMO) Reports Q3 Loss of $0.27; Guides
TomoTherapy Incorporated (NASDAQ: TOMO) reports Q3 loss of $0.27, versus the analyst estimate of $0.20. Revenue for the quarter was $34.40 million, which compares to the estimate of $40.28 million.
Sees Q4 loss $0.6 - $0.23, versus $0.14 previously
Sees Q4 loss $0.6 - $0.23, versus $0.14 previously
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Pandora (P) Blows Up Expectations as Listener Hours Rip; Guides FY13 Ahead of Views
- Hewlett-Packard Company (HPQ) Tops Q2 EPS by 7c; Guides Q3 Below the Street, Raises FY12 Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
